QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)

Tonix Pharmaceuticals (TNXP) Competitors

$0.34
+0.02 (+6.17%)
(As of 02/26/2024 ET)

TNXP vs. GRTX, BNOX, NEXI, ASLN, ERNA, AEZS, BCEL, VCNX, TRVN, and ABVC

Should you be buying Tonix Pharmaceuticals stock or one of its competitors? The main competitors of Tonix Pharmaceuticals include Galera Therapeutics (GRTX), Bionomics (BNOX), NexImmune (NEXI), ASLAN Pharmaceuticals (ASLN), Eterna Therapeutics (ERNA), Aeterna Zentaris (AEZS), Atreca (BCEL), Vaccinex (VCNX), Trevena (TRVN), and ABVC BioPharma (ABVC). These companies are all part of the "pharmaceutical preparations" industry.

Tonix Pharmaceuticals vs.

Galera Therapeutics (NASDAQ:GRTX) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, community ranking, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

42.3% of Galera Therapeutics shares are held by institutional investors. Comparatively, 5.8% of Tonix Pharmaceuticals shares are held by institutional investors. 6.9% of Galera Therapeutics shares are held by company insiders. Comparatively, 0.5% of Tonix Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Tonix Pharmaceuticals had 7 more articles in the media than Galera Therapeutics. MarketBeat recorded 8 mentions for Tonix Pharmaceuticals and 1 mentions for Galera Therapeutics. Galera Therapeutics' average media sentiment score of 0.23 beat Tonix Pharmaceuticals' score of 0.00 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Galera Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Tonix Pharmaceuticals
0 Very Positive mention(s)
4 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Galera Therapeutics currently has a consensus target price of $9.00, indicating a potential upside of 4,587.50%. Tonix Pharmaceuticals has a consensus target price of $8.00, indicating a potential upside of 2,223.56%. Given Tonix Pharmaceuticals' higher possible upside, equities analysts plainly believe Galera Therapeutics is more favorable than Tonix Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galera Therapeutics
1 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.75
Tonix Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Tonix Pharmaceuticals' return on equity of 0.00% beat Galera Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Galera TherapeuticsN/A N/A -146.85%
Tonix Pharmaceuticals N/A -76.36%-68.78%

Galera Therapeutics has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals has a beta of 2.23, suggesting that its share price is 123% more volatile than the S&P 500.

Galera Therapeutics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galera TherapeuticsN/AN/A-$62.22M-$1.89-0.10
Tonix PharmaceuticalsN/AN/A-$110.22M-$11.26-0.03

Tonix Pharmaceuticals received 288 more outperform votes than Galera Therapeutics when rated by MarketBeat users. Likewise, 65.00% of users gave Tonix Pharmaceuticals an outperform vote while only 54.35% of users gave Galera Therapeutics an outperform vote.

CompanyUnderperformOutperform
Galera TherapeuticsOutperform Votes
50
54.35%
Underperform Votes
42
45.65%
Tonix PharmaceuticalsOutperform Votes
338
65.00%
Underperform Votes
182
35.00%

Summary

Tonix Pharmaceuticals beats Galera Therapeutics on 9 of the 15 factors compared between the two stocks.


Get Tonix Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TNXP vs. The Competition

MetricTonix PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$9.21M$6.80B$4.90B$7.44B
Dividend YieldN/A2.78%2.92%3.86%
P/E Ratio-0.0311.76204.2116.28
Price / SalesN/A953.163,426.91176.57
Price / CashN/A17.9525.2325.75
Price / Book0.025.314.554.66
Net Income-$110.22M$158.82M$110.17M$209.91M
7 Day Performance-9.75%2.70%2.17%0.65%
1 Month Performance13.26%10.29%10.33%5.59%
1 Year Performance-91.39%4.38%11.80%6.92%

Tonix Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GRTX
Galera Therapeutics
0.7607 of 5 stars
$0.17
flat
$7.75
+4,354.0%
-89.5%$9.46MN/A-0.0931Gap Down
BNOX
Bionomics
1.8912 of 5 stars
$1.17
+20.6%
$9.80
+737.6%
-66.9%$9.55M$10,000.000.00N/AGap Up
NEXI
NexImmune
0 of 5 stars
$9.02
-9.3%
N/A-38.4%$9.56MN/A-0.2122Gap Up
ASLN
ASLAN Pharmaceuticals
1.6571 of 5 stars
$0.56
+1.8%
$15.67
+2,713.7%
-90.3%$9.10MN/A-0.1934
ERNA
Eterna Therapeutics
0 of 5 stars
$1.67
-2.9%
N/A-57.3%$9.04MN/A-0.409Gap Down
AEZS
Aeterna Zentaris
2.0972 of 5 stars
$1.85
+2.8%
$15.00
+710.5%
-43.2%$8.99M$5.64M-0.3811Analyst Report
News Coverage
BCEL
Atreca
3.4325 of 5 stars
$0.25
+8.6%
$10.75
+4,171.0%
-78.4%$9.97MN/A-0.1090Gap Down
VCNX
Vaccinex
1.8627 of 5 stars
$0.80
+6.6%
N/A-92.1%$10.02M$280,000.00-0.1338Stock Split
High Trading Volume
TRVN
Trevena
1.8985 of 5 stars
$0.59
+1.7%
$5.50
+833.8%
-47.1%$10.18M$570,000.00-0.2135Analyst Report
News Coverage
ABVC
ABVC BioPharma
0 of 5 stars
$1.32
-1.5%
N/A-82.7%$10.22M$970,000.00-0.3719Gap Down

Related Companies and Tools

This page (NASDAQ:TNXP) was last updated on 2/26/2024 by MarketBeat.com Staff